Conatus Pharmaceuticals Inc (CNAT) Given Consensus Recommendation of “Buy” by Brokerages

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has been assigned a consensus rating of “Buy” from the eight research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $12.62.

CNAT has been the subject of a number of research analyst reports. Seaport Global Securities reissued a “buy” rating and set a $16.00 price target on shares of Conatus Pharmaceuticals in a research note on Friday, October 6th. HC Wainwright reissued a “buy” rating and set a $17.00 price target (down from $18.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, November 2nd. Zacks Investment Research lowered Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th. Finally, S&P Equity Research raised their price target on Conatus Pharmaceuticals from $5.02 to $5.69 in a research note on Wednesday, January 24th.

Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) opened at $5.17 on Friday. Conatus Pharmaceuticals has a one year low of $3.88 and a one year high of $9.40. The company has a current ratio of 2.69, a quick ratio of 2.69 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $159.03, a P/E ratio of -6.38 and a beta of 1.25.

Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.08). Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. The business had revenue of $9.57 million for the quarter, compared to the consensus estimate of $16.06 million. During the same period in the prior year, the business posted ($0.31) earnings per share. analysts anticipate that Conatus Pharmaceuticals will post -0.65 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CNAT. Voya Investment Management LLC purchased a new position in Conatus Pharmaceuticals during the 2nd quarter worth $101,000. Wells Fargo & Company MN increased its holdings in Conatus Pharmaceuticals by 3,098.0% during the 3rd quarter. Wells Fargo & Company MN now owns 19,188 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 18,588 shares during the period. New York State Common Retirement Fund increased its holdings in Conatus Pharmaceuticals by 156.4% during the 3rd quarter. New York State Common Retirement Fund now owns 24,100 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 14,700 shares during the period. Rhumbline Advisers purchased a new position in Conatus Pharmaceuticals during the 2nd quarter worth $156,000. Finally, OxFORD Asset Management LLP purchased a new position in Conatus Pharmaceuticals during the 2nd quarter worth $230,000. Institutional investors own 35.84% of the company’s stock.

WARNING: This story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://sportsperspectives.com/2018/02/03/conatus-pharmaceuticals-inc-cnat-given-consensus-recommendation-of-buy-by-brokerages.html.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply